Back to Search
Start Over
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
- Source :
-
Blood [Blood] 2017 Jun 08; Vol. 129 (23), pp. 3071-3073. Date of Electronic Publication: 2017 Mar 29. - Publication Year :
- 2017
-
Abstract
- Primary central nervous system (CNS) lymphoma (PCNSL) and primary testicular lymphoma (PTL) are rare extranodal large B-cell lymphomas with similar genetic signatures. There are no standard-of-care treatment options for patients with relapsed and refractory PCNSL and PTL, and the overall prognosis is poor. PCNSLs and PTLs exhibit frequent 9p24.1 copy-number alterations and infrequent translocations of 9p24.1 and associated increased expression of the programmed cell death protein 1 (PD-1) ligands, PD-L1 and PD-L2. The activity of PD-1 blockade in other lymphomas with 9p24.1 alterations prompted us to test the efficacy of the anti-PD1 antibody, nivolumab, in 4 patients with relapsed/refractory PCNSL and 1 patient with CNS relapse of PTL. All 5 patients had clinical and radiographic responses to PD-1 blockade, and 3 patients remain progression-free at 13 <superscript>+</superscript> to 17 <superscript>+</superscript> months. Our data suggest that nivolumab is active in relapsed/refractory PCNSL and PTL and support further investigation of PD-1 blockade in these diseases.<br /> (© 2017 by The American Society of Hematology.)
- Subjects :
- Aged
Aged, 80 and over
Antibodies, Monoclonal adverse effects
Antineoplastic Agents adverse effects
Central Nervous System Neoplasms diagnostic imaging
Humans
Lymphoma, B-Cell diagnostic imaging
Male
Middle Aged
Neoplasm Recurrence, Local diagnostic imaging
Neoplasm Recurrence, Local therapy
Nivolumab
Programmed Cell Death 1 Receptor immunology
Testicular Neoplasms diagnostic imaging
Tomography, X-Ray Computed
Treatment Outcome
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents therapeutic use
Central Nervous System Neoplasms therapy
Lymphoma, B-Cell therapy
Programmed Cell Death 1 Receptor antagonists & inhibitors
Testicular Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1528-0020
- Volume :
- 129
- Issue :
- 23
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Academic Journal
- Accession number :
- 28356247
- Full Text :
- https://doi.org/10.1182/blood-2017-01-764209